Table 3: Factors Related To Platelet Nadir Depths
|
Parameters |
PLT count nadir depths (cycle 1) |
PLT count nadir depths (cycle 2) |
||
|
Median(Range) x109/L |
P Value |
Median(Range) x109/L |
P Value |
|
|
Age groups (years) |
||||
|
14-24* |
36 (4-95) |
p=0.011 |
63.0(-89 to 436) |
p=0.728 |
|
25-34 |
207 (16-341) |
132.0(85-322) |
||
|
35-44 |
183 (-68 to 542) |
160.0(45-426) |
||
|
45-54 |
173 (0-289) |
156.0(-17 to 393) |
||
|
55-64* |
77·5 (-109 to 198) |
174.0(17-464) |
||
|
65-74 |
159 (53-218) |
159.0(64-467) |
||
|
Diagnosis/Therapy |
||||
|
NHL/ CHOP |
159 (1-542) |
p=0.952 |
113.0(-89 to 467)† |
p=0.024 |
|
Breast Ca/ AC |
176 (-109 to 339) |
160.0(-17 to 467)† |
||
|
Baseline PLT counts (x109/L) |
||||
|
100-149 |
7 (-44 to 11) |
p<0005 |
60.0(-17 to 64) |
p<0005 |
|
150-249 |
47·5 (-34 to 106) |
149.3(66-174) |
||
|
250-349 |
176·5 (-109 to 191) |
156.0(-89 to 284) |
||
|
350-449 |
197 (-1 to 295) |
313.5(63-403) |
||
|
>449 |
275 (57-542)‡ |
392.7(152-467)‡ |
||
NHL, non-Hodgkin’s lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; AC, doxorubicin, cyclophosphamide; Breast Ca, breast cancer; PLT, platelet; TLC, total lymphocyte count; PLT nadir count depth, drop in PLT count from baseline to nadir values. *Patients in the 14-24 and 55-64 age groups had smaller PLT count nadir depth values compared to patients in the rest of the age groups in cycle 1, †AC therapy for breast cancer had greater PLT count nadir depths than CHOP for NHL in cycle 2; ‡high baseline PLT counts were associated with greater PLT count nadir depths in both cycles.